Samuel Anim, MD

About

Samuel Odame Anim MD, MSC, FAAP, is a hematologist and oncologist at University Hospitals and is the director of the Adult Sickle Cell Program at UH Seidman Cancer Center. He is board-certified in general pediatrics and pediatric hematology-oncology.

Dr. Anim earned a Bachelor of Science degree followed by his medical degree at Kwame Nkrumah University of Science and Technology in Kumasi, Ghana. He went on to earn a Master’s degree in hematology at the University of Westminster in London. Dr. Anim did his residency training in pediatrics at the Western Michigan University Homer Stryker M.D. School of Medicine (formerly Michigan State University Kalamazoo Center for Medical Studies), where he was named pediatric chief resident and earned the Resident Teaching Excellence Award. He then completed a fellowship in pediatric hematology/oncology and Washington University School of Medicine in St. Louis. His fellowship research was focused on asthma in sickle cell disease.

Prior to joining University Hospitals, Dr. Anim was an attending pediatric hematologist-oncologist at Sanford Roger Maris Cancer Center in Fargo, N.D. He was also the head of the Department of Pediatric Hematology Oncology and the co-director of the Sanford Bleeding Disorders and Sickle Cell Disease Clinic, providing lifespan care for individuals with sickle cell disease and bleeding disorders. In 2018, he was awarded the New to Sanford Physician Award, presented to a physician who is within his or her first five years at Sanford Health and has made a significant contribution in that time.

Dr. Anim is a member of several professional organizations and committees, including the American Academy of Pediatrics, the American Society of Hematology, the American Society of Pediatric Hematology/Oncology, and the Children’s Oncology Group. His clinical research interests include sickle cell disease, immunotherapy, and other areas of pediatric hematology/oncology. His experience includes being the principal investigator for the Childrens Oncology Group and several sickle cell clinical trials.